AstraZeneca said its COVID-19 vaccine is 76 percent effective for preventing symptomatic illness after a new analysis of updated U.S. trial results.
Previously, it announced the efficacy as 79 per cent. Doubts were expressed by a top US-based health agency over the Covid-19 vaccine trial data. The US-based National Institute of Allergy and Infectious Diseases (NIAID) expressed concern that AstraZeneca may have provided outdated information on the efficacy data related to the clinical trial of its Covid-19 vaccine
The board said that it is concerned over the information released by AstraZeneca on the initial data from the clinical trial of its Covid-19 vaccine.
